Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children

G Bedogni1, A Gastaldelli, M Manco

  • 1Centro Studi Fegato, Basovizza e Dipartimento ACADEM, Università di Trieste, Trieste, Italy.

Insights

Non-alcoholic fatty liver disease (NAFLD) affects 41% of obese children and is linked to increased insulin resistance. This condition, however, was not associated with impaired beta-cell function in the study.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Hepatology

Background:

  • Early-onset type 2 diabetes mellitus (T2DM) is linked to obesity, insulin resistance, and impaired beta-cell function.
  • Non-alcoholic fatty liver disease (NAFLD) is a potential independent risk factor for T2DM.
  • Investigating NAFLD's impact on glucose metabolism in obese children is crucial.

Purpose of the Study:

  • To examine the association between NAFLD and glucose metabolism in obese children.
  • To determine if NAFLD is an independent predictor of metabolic dysfunction in pediatric obesity.

Main Methods:

  • A cohort of 571 obese children (aged 8-18) underwent liver ultrasonography to diagnose NAFLD.
  • Oral-glucose tolerance testing (OGTT) assessed glucose metabolism; insulin sensitivity index (ISI) and beta-cell function (incAUCins/incAUCglu) were evaluated.
  • Multivariable regression analysis controlled for confounders like BMI, age, and pubertal status.

Main Results:

  • NAFLD was diagnosed in 41% of obese children.
  • Children with NAFLD showed higher rates of impaired glucose tolerance or T2DM (25% vs. 8%).
  • NAFLD was independently associated with higher 120-min OGTT glucose and lower ISI, but not impaired beta-cell function.

Conclusions:

  • NAFLD is prevalent in obese children and correlates with increased insulin resistance.
  • NAFLD in obese children is not significantly associated with impaired beta-cell function.
  • Findings highlight NAFLD as a key metabolic concern in pediatric obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...